Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium

Multiple Sclerosis Journal

Volumn 17, Issue 6, 2011, Pages 725-733

  Kister, Ilya ^a,d   Chamot, Eric ^b   Bacon, Joshua H ^a,c   Cutter, Gary ^b   Herbert, Joseph ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c YESHIVA UNIVERSITY   (United States)

^d NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

autoimmune diseases; multiple sclerosis; natural history studies (prognosis); prognosis; risk factors in epidemiology

Indexed keywords

ADULT; AGE; ARTICLE; DISEASE DURATION; DISEASE SEVERITY; ETHNICITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS SEVERITY SCORE; SCORING SYSTEM;

EID: 79959408812     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458510396269     Document Type: Article

References (19)

1. Compston A, McDonald IR, Noseworthy J, Lassmann H, Miller DH, Smith KJ, Wekerle H, Confavreux C McAlpine's Multiple Sclerosis. 4 th ed Churchill Livingstone ; 2005 :
2. Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, Rodriguez M. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology. 2004 ; 62 (4). 601-606 (Pubitemid 38252802)
3. Kappos L, Traboulsee A, Constantinescu C, Erälinna J, Forrestal F, Jongen P, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006 ; 67 (6). 944-953 (Pubitemid 44454583)
4. Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010 ; 16 (3). 342-350
5. Ebers G, Rice G, Konieczny A, et al. The Interferon beta-1b 16-year long-term follow-up study: the final results. Neurology. 2006 ; 66 ( Suppl. 2 ):
6. Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol. 2009 ; 66 (4). 513-520
7. Veugelers PJ, Fisk JD, Brown MG, Stadnyk K, Sketris IS, Murray TJ, Bhan V. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation. Mult Scler. 2009 ; 5 (11). 1286-1294
8. Roxburgh RHSR, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005 ; 64 (7). 1144-1151
9. Jacobs LD, Wende KE, Brownscheidle CM, Apatoff B, Coyle PK, Goodman A, et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler. 1999 ; 5 (5). 369-376 (Pubitemid 29505053)
10. Koenker R Quantile regression. Cambridge, UK: Cambridge University Press ; 2005 :
11. Vansteelandt S. Estimating direct effects in cohort and case-control studies. Epidemiology. 2009 ; 20 (6). 851-860
12. Kister I, Chamot E, Bacon JH, Niewczyk PM, De Guzman RA, et al. Rapid disease course in African-Americans with Multiple Sclerosis. Neurology. 2010 20 ; 75 (3). 217-223
13. Kister I, Bacon T, Chamot E, Cutter G, Butzkueven H, Herbert J, et al. Multiple Sclerosis Severity Scores Decrease with Calendar Year of First EDSS Assignment in MSBase. Mult Scler. 2010 ; 16 (S10). S208 - S208
14. Debouverie M, Laforest L, Van Ganse E, Guillemin F. Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatients. Mult Scler. 2009 ; 15 (2). 251-257
15. Sormani MP, Tintorè M, Rovaris M, Rovira A, Vidal X, Bruzzi P, et al. Will Rogers phenomenon in multiple sclerosis. Ann Neurol. 2008 ; 64 (4). 428-433
16. Johnson EO, Schultz L. Forward telescoping bias in reported age of onset: an example from cigarette smoking. Int J Methods Psychiatr Res. 2005 ; 14 (3). 119-129 (Pubitemid 41448727)
17. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002 ; 58 (2). 169-178 (Pubitemid 34086933)
18. Noseworthy JH. How much can we learn from long-term extension trials in multiple sclerosis?. Neurology. 2006 26 ; 67 (6). 930-931 (Pubitemid 44454578)
19. Parkin DM. The role of cancer registries in cancer control. Int J Clin Oncol. 2008 ; 13 (2). 102-111 (Pubitemid 351668181)